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Introductory Chapter: Opioid 




Opiates have been used for various purposes throughout history [1, 2] 
(Figure 1). Interest in opium poppy plant (Papaver somniferum) arose more than 
4500 years ago, due to the nutritional power of its seeds. Afterwards, around 
1550 BC, opium was used in the Eastern Mediterranean and Egypt for religious and 
medicinal purposes. Greek medicine was the first to refer to opium as a narcotic, 
and it is at this time that a classification of the various preparations of this plant 
begins. In the seventeenth century, its use as a pain reliever in Sydenham’s laudanum 
began to become general, until it was replaced by the currently used morphine 
hydrochloride.
In 1803, the German pharmacist, Friedrich Wilhelm Adam Sertürner, identi-
fied and isolated the major psychoactive agent in opium, at approximately 4–21% 
and named it “morphium,” alluding to the Greek god of dreams Morpheus [3]. 
Sertürner and three young assistant experimented the narcotic effects of morphine 
by taking the raw material. From this moment on, morphine began to be used for 
the same cases in which opium was used through different routes of administration 
(oral, rectal, or transdermal). Twenty years after Sertürner’s discovery, in 1820, a 
pharmacist named Heinrich Emmanuel Merck began to commercialize morphine. 
The medical use of morphine was widespread after the discovery of the hypodermic 
syringe in the mid-nineteenth century.
In 1973, three independent research groups headed by Solomon Snyder in 
Baltimore, Eric Simon in New York, and Lars Terenius in Sweden confirmed the 
existence of specific opioid receptors [4–6], and, 2 years later, Hughes discovered 
the presence of endogenous peptides able of activating the same receptors, although 
in a less intense way [7].
The endogenous opioid system plays a main role in multiple physiological 
functions of the organism. When people carry out certain daily activities (eating, 
exercising, sexual behavior and others), endogenous opioids are released, induc-
ing a brain reward effect that increases the likelihood that these behaviors tend to 
repeat. It is the so-called behavioral reinforcing effect, which can lead to addictive 
behaviors.
Nowadays, morphine is widely used for chronic to severe pain relief in many 
conditions associated with heart attacks, serious injury, postoperative discomfort, 
and terminal illness such as cancer [8]. However, it is not possible to uncouple its 
beneficial analgesic effect from addiction, tolerance, and dependence. Being able to 
separate the potent analgesia from the addictive capacity would make pain relief to 
be a minor medical problem.
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2. Opioid receptors
There are three main opioid receptor types that produce pharmacologic effects 
upon stimulation, mu (MOP), kappa (KOP), and delta (DOR), and morphine is a 
MOR-preferring agonist. The novel nociception/orphanin FQ receptor is consid-
ered to be a non-opioid branch of the opioid receptor family (Figure 2). However, 
substantial pharmacological evidence for additional opioid receptor phenotypes 
exists [9].
Opioid receptors are a group of Gi/Go protein-coupled receptors, which consist 
of seven transmembrane domains, three extracellular, and three intracellular loops, 
extracellular amino acid N-terminus, and intracellular carboxyl C-terminus. They 
are activated both by endogenously opioid peptides and by exogenously admin-
istered natural, synthetic, or semisynthetic opiate compounds such as morphine 
and heroin.
Opioid receptors are located in both the central and peripheral nervous system. 
Morphine analgesia is mainly due to its action on MOP receptors, although the 
activation of KOP and DOP receptors also participates in the analgesic effects of this 
drug. These receptors act synergistically in different places at CNS level, from the 
spinal cord to the cerebral cortex, inhibiting the nociceptive sensation whatever its 
location or intensity. Specifically, they act on the afferent system at the spinal level, 
where the activation of MOP receptors results in the inhibition of primary sensory 
fibers. Morphine also acts by regulating the transmission of the efferent system, 
inhibiting the nociceptive transmission sent from mesencephalic areas and the 
brainstem. Nevertheless, opiates not only diminish the painful sensation but also 
Figure 2. 
Opioid receptor structures. Modified from [10].
Figure 1. 
Timeline of morphine history.
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block the unpleasant or distressing feelings that accompany pain through its action 
at the limbic and cortical level, areas involved in emotional physiological responses 
and where a large number of opioid receptors are expressed.
Some pharmacological properties of opioid agonists are routinely used in clinic 
practice. In addition to the aforementioned opioid analgesic power, these drugs 
have utility in other conditions as cough suppressant, antidiarrheal, emetic, and 
anesthetics, being also used in special situations as in the acute pulmonary edema or 
in respiratory rhythm regulation in patients undergoing artificial respiration.
3. Genetic polymorphisms modulating the pain response
Recent research in the field of pharmacogenomics has discovered important 
single-nucleotide polymorphisms that are thought to be linked to opioid dose vari-
ability. This could explain the genetic changes in the analgesic opioid dose. These 
polymorphisms appear in several areas involved in pain pathways, drug receptors, 
drug-metabolizing enzymes, and drug efflux molecules [11]. Among the genetic 
polymorphisms identified as possible modulators of the pain response, we can 
mention genes that code for voltage-gated sodium channels, the metabolic enzyme 
catechol-O-methyltransferase (COMT), the synthetic enzyme CTP cyclohydrolase, 
and the changes described in the OPRM1 gene [12].
A better knowledge of these polymorphisms can help clinicians to manage 
interindividual variability in opioid demands. These genetic markers could also help 
to design tools to precisely predict the analgesic opioid dose, increase efficacy, and 
reduce the incidence of drug dependence and addiction.
4. Opioid addiction: a severe substance use disorder
Today, morphine is a Schedule II narcotic, along with other drugs like fentanyl, 
hydromorphone, meperidine, methadone, or oxycodone, under the Controlled 
Substances Act (US Drug Enforcement Administration) [13], and is available only 
by a prescription due to its high potential for abuse. Morphine is also regulated 
because it is the precursor to heroin, a synthetic alkaloid that presents a different 
pharmacokinetics than morphine, resulting in more acute CNS effects, partly 
responsible for the tremendous addictive capacity of this molecule.
The first experiences with opioids are usually unpleasant, since the effects on 
the gastrointestinal tract (nausea and vomiting) predominate. However, when 
repeating the behavior, tolerance to the emetic action develops, then the feeling of 
euphoria prevails.
The addictive state is characterized by the compulsive consumption of the drug 
despite the serious negative consequences that it entails, such as diseases, neglect-
ing social and family obligations, and the need to commit criminal acts to obtain 
the substance. For drug addicts, drugs become the main incentive within their 
scale of values, and, as a result, their lives are reduced to obtaining and consum-
ing drugs.
In addition, drug addiction involves loss of control in limiting intake and emerg-
ing of a negative emotional state (e.g., dysphoria, anxiety and irritability), reflect-
ing a motivational withdrawal syndrome when access to the drug is prevented [14].
The addictive process consists of three stages (Figure 3): binge/intoxication, 
withdrawal/negative affect, and preoccupation/anticipation (craving). These stages 
interact with each other, becoming more intense and ultimately leading to the state 
known as addiction.
Opioids - From Analgesic Use to Addiction
4
In the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), addic-
tion is synonymous with a severe substance use disorder, and opioid use disorder is 
included here [15]. Just like it happens with other substance use disorders, individu-
als can begin opioid misuse with recreational use of the drug and evolve to the 
withdrawal/negative affect stage as negative reinforcement appear.
Despite numerous treatment attempts and the serious risk to their lives, relapses 
to drug-seeking and drug-taking behaviors following months or years of abstinence 
are frequent when addicts find stimuli associated with the first contact with the 
drug [16]. This fact shows that we need more effective long-term treatments for 
drug dependence and emphasizes, on the other hand, the importance of better 
understanding the neurobiological mechanisms that underlie drug addiction and 
their persistence.
5. The opioid epidemic: challenges and opportunities
Over the past 20 years, there has been a significant increase in opioid prescrip-
tion worldwide, but especially in the United States. This substantial increase in opi-
oid prescribing patterns has been due, in part, to the influence of certain currents 
of opinion, which trivialized the potential drawbacks of opioid painkillers, along 
with the widely spread belief that any kind of pain could and should be treated with 
opioids. On the other hand, consuming higher doses than prescribed or by people 
who had not been prescribed, or switching to a more direct route of administration 
than the oral route, has contributed to the expansion of the abuse of these drugs 
among the population [17].
An opioid epidemic has been declared in 2017 in the United States [1, 18]. 
Europe and, particularly, low- and middle-income countries, appear to be less 
influenced by this problem. An estimated 10.3 million Americans aged 12 and older 
misused opioids in 2018, including 9.9 million prescription pain reliever (mor-
phine, oxycodone, and hydrocodone) abusers and 808,000 heroin users. A report 
from the Centers for Disease Control and Prevention (CDC) indicated that opioid 
Figure 3. 
Neurobiological bases of substance use disorders [14].
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sales multiplied by 14 from 1999 to 2010. Moreover, this center reported that, in 
2017, the number of overdose deaths involving opioids (including prescription and 
illegal opioids) was six times higher than in 1999. Prescription opioid overdose, 
abuse, and dependence involve high economic costs for American society from 
around $78.5 billion.
Avoiding prescription of opioid pain relievers when its therapeutic indication 
is doubtful or unnecessary is always easier than proceeding later upon treatments 
for abuse, which will be even more difficult if the patient is not involved. Only in 
certain situations, opioid administration for pain relieve is essential; for all the 
others, a great diversity of interventions that can be as effective or more than the 
prescription of opioids are available, avoiding thus the potential risks of addiction 
and overdose that are associated with the consumption of opiates.
Different states have begun implementing prescription drug monitoring pro-
grams to control irregular prescribing practices by clinicians and the recreational 
use of opioids. In addition, current strategies include a greater involvement of 
healthcare professionals (such as psychiatrists) and approaches to address comor-
bidities [19]. These measures could be resulting in a decrease in opioid prescription, 
as shown in last reports from CDC, which indicate a reduction in these prescrip-
tions from 2016 [20].
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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